SEARCH

SEARCH BY CITATION

Bibliography

  • 1
    Anand BS, Raed AK & Malaty HM, et al. Low point prevalence of peptic ulcer in normal individuals with Helicobacter pylori infection. Am J Gastroenterol 1996; 91: 11125.
  • 2
    Vaira D, Miglioli M & Mule P, et al. Prevalence of peptic ulcer in Helicobacter pylori positive blood donors. Gut 1994; 35: 30912.
  • 3
    El-Omar EM, Penman ID, Ardill JE, Chittajallu RS, Howie C & McColl KE. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109: 68191.
  • 4
    Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994; 89: S11628.
  • 5
    Blaser MJ. In a world of black and white, Helicobacter pylori is gray. Ann Int Med 1999; 130: 6957.
  • 6
    Lanas AI, Remacha B, Esteva F & Sainz R. Risk factors associated with refractory peptic ulcers. Gastroenterology 1995; 109: 112433.
  • 7
    Hirschowitz BI & Lanas A. Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. Gastroenterology 1998; 114: 88392.
  • 8
    Lanas A, Sekar MC & Hirschowitz BI. Objective evidence of aspirin use in both ulcer and non-ulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992; 103: 8629.
  • 9
    Lanas A, Serrano P, Bajador E, Esteva F, Benito R & Sainz R. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997; 112: 6839.
  • 10
    Hirschowitz BI, Mohnen J & Shaw S. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. Aliment Pharmacol Ther 1996; 10: 497506.
  • 11
    Hirschowitz BI, Mohnen J & Shaw S. Long-term treatment with lansoprazole for patients with Zollinger–Ellison syndrome. Aliment Pharmacol Ther 1996; 10: 50722.
  • 12
    Weber HC, Venzon DJ, Jensen RT & Metz DC. Studies on the interrelation between Zollinger–Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy. Gastroenterology 1997; 112: 8491.
  • 13
    Saeed ZA, Evans Jr DJ & Evans DG, et al. Helicobacter pylori and Zollinger–Ellison syndrome. Dig Dis Sci 1991; 36: 158.
  • 14
    Hirschowitz B. Clinical course of nonsurgically treated Zollinger–Ellison syndrome In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas. Basel: Karger, 1995: 36–371.
  • 15
    Jensen R & Gardner J. Zollinger–Ellison syndrome: clinical presentation. Pathology, Diagnosis, and Treatment. New York: Armonk Academic Research Association, 1991.
  • 16
    Eissele R, Brunner G, Simon B, Solcia E & Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 70717.
  • 17
    Kuipers EJ, Uyterlinde AM & Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995; 90: 14016.
  • 18
    Kuipers EJ, Lundell L & Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 101822.
  • 19
    Lundell L, Miettinen P & Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999; 117: 31926.
  • 20
    Diebold M-D, Richardson S, Duchateau A & Bigard M-A, et al. Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls. Dig Dis Sci 1998; 43: 162935.
  • 21
    Kirkpatrick Jr PM & Hirschowitz BI. Duodenal ulcer with unexplained marked basal gastric acid hypersecretion. Gastroenterology 1980; 79: 410.
  • 22
    Hirschowitz BI & Groarke J. Vagal effects on acid and pepsin secretion and serum gastrin in duodenal ulcer and controls. Dig Dis Sci 1993; 38: 187484.
  • 23
    Dixon MF, Genta RM, Yardley JH & Correa P. Histological classification of gastritis and Helicobacter pylori infection: an agreement at last? The International Workshop on the Histopathology of Gastritis. Helicobacter 1997; 2(Suppl. 1): S1724.
  • 24
    Brinn N. Rapid metallic histologic staining using the microwave oven. J Histotechnol 1983; 6: 1259.
  • 25
    D’Adda T, Pilato FP, Lazzaroni M, Robutti F, Bianchi-Porro G & Bordi C. Ultrastructural morphometry of gastric endocrine cells before and after omeprazole. A study in the oxyntic mucosa of duodenal ulcer patients. Gastroenterology 1991; 100: 156370.
  • 26
    Solcia E, Bordi C & Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41: 185200.
  • 27
    Solcia E, Rindi G, Havu N & Elm G. Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole. Scand J Gastroenterol Suppl 1989; 166: 12937.
  • 28
    Solcia E, Villani L & Fiocca R, et al. Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scand J Gastroenterol 1994; 201(Suppl. 205): 2834.
  • 29
    Fiocca R, Villani L & Luinetti O, et al. Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: a morphological approach to the study of ulcerogenesis in man. Virchows Arch a Pathol Anat Histopathol 1992; 420: 48998.
  • 30
    McColl KE, Nujumi AM, Dorrian CA, Macdonald AM, Fullarton GM & Harwood J. Helicobacter pylori and hypergastrinemia during proton pump inhibitor therapy. Scand J Gastroenterol 1992; 27: 938.
  • 31
    Fich A, Talley NJ, Shorter RG & Phillips SF. Zollinger–Ellison syndrome. Relation to Helicobacter pylori-associated chronic gastritis and gastric acid secretion. Dig Dis Sci 1991; 36: 104.
  • 32
    Lehy T, Mignon M & Cadiot G, et al. Gastric endocrine cell behavior in Zollinger–Ellison patients upon long-term potent antisecretory treatment. Gastroenterology 1989; 96: 102940.
  • 33
    Lamberts R, Creutzfeldt W, Struber HG, Brunner G & Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 135670.
  • 34
    D’Adda T, Pilato FP, Lazzaroni M, Robutti F, Bianchi-Porro G & Bordi C. Ultrastructural morphometry of gastric endocrine cells before and after omeprazole. A study in the oxyntic mucosa of duodenal ulcer patients. Gastroenterology 1991; 100: 156370.
  • 35
    Solcia E, Fiocca R, Havu N, Dalvag A & Carlsson R. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992; 51: 8292.
  • 36
    Havu N, Maaroos HI & Sipponen P. Argyrophil-cell hyperplasia associated with chronic corpus gastritis in gastric ulcer disease. Scand J Gastroenterol 1991; 26(Suppl. 186): 904.
  • 37
    Sachs G. Gastritis, Helicobacter pylori, and proton pump inhibitors. Gastroenterology 1997; 112: 10336(Editorial).
  • 38
    Kuipers EJ, Klinkenberg-Knol EC & Festen HP, et al. Long-term omeprazole therapy does not affect Helicobacter pylori status in most patients. Scand J Gastroenterol 1993; 28: 97880.
  • 39
    Verdu EF, Armstrong D & Idstrom JP, et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995; 37: 7438.
  • 40
    Stolte M, Meining A, Schmitz JM, Alexandridis T & Seifert E. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998; 12: 24753.DOI: 10.1046/j.1365-2036.1998.00310.x
  • 41
    Genta RM, Lew GM & Graham DY. Changes in the gastric mucosa following eradication of Helicobacter pylori. Mod Pathol 1993; 6: 2819.
  • 42
    Solcia E, Fiocca R, Villani L, Gianatti A, Cornaggia M & Chiaravalli A. Morphology and pathogenesis of endocrine hyperplasias, precarcinoid lesions and carcinoids arising in chronic atrophic gastritis. Scand J Gastroenterol 1991; 26(Suppl. 180): 14659.
  • 43
    Waldum H, Sandvik A & Idle J. Gastrin is the most important factor in ECL tumorigenesis. Gastroenterology 1998; 114: 11134.
  • 44
    Debelnko L, Emmert-Buck M & Lubensky I. Reply: Gastrin is the most important factor in ECL tumorigenesis. Gastroenterology 1998; 114: 11145.
  • 45
    Hirschowitz BI. Clinical aspects of ECL cell abnormalities. Presented at Symposium on ‘the Biological and Clinical Relevance of the Gastric Enterochromaffin-Like (ECL) Cell’. The Yale J Biol Med 1998; 71: 30310.
  • 46
    Annibale B, Aprile MR & Ferrara G, et al. Relationship between fundic endocrine cells and gastric acid secretion in hypersecretory duodenal ulcer diseases. Ailment Pharmacol Ther 1998; 12: 77988.
  • 47
    Solcia E, Capella C, Fiocca R, Rindi G & Rosai J. Gastric argyrophil carcinoidosis in patients with Zollinger–Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol 1990; 14: 50313.
  • 48
    Maton PN, Lack EE & Collen MJ, et al. The effect of Zollinger–Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology 1990; 99: 94350.